A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
← catalyst calendarNCT06646276 · readout in 595 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
530estimated
Sites
183
Countries
Argentina, Australia, Austria +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-25 | actual | When the study began enrolling |
| Primary completion | 2028-04-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-09-05 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Extensive-Stage Small Cell Lung Cancer
Interventions
- Biological: BMS-986489 (BMS-986012+Nivolumab)
- Biological: Atezolizumab
- Drug: Carboplatin
- Drug: Etoposide
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to 5 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed